TrialCompass TCL
Back to results
RecruitingPriority 4 · Lower priorityNCT06436677

A Study of Molecular Subtyping-based Therapeutic Strategies for Cutaneous T-cell Lymphoma

ClinicalTrials.gov

Plain-language summary

This trial is studying molecular subtype based treatment for people with cutaneous T-cell lymphoma (skin lymphoma). The study measures how well this treatment works and monitors for side effects. This trial does not currently list US sites.

Who can join (key eligibility)

  • Age 18 Years to 75 Years years
  • See full trial listing for complete eligibility

Final eligibility is determined by the trial team. This list is a starting point only.

What's being tested

molecular subtype based treatment (OTHER): The immunohistochemistry algorithm established by the previous research group was used to determine the molecular subtype, and the corresponding treatment plan was selected according to the subtype. Such as for TCyEM patients, interferon-based immunomodulatory therapy was selected, and TCM-type patients were treated with retinoids.

Drugs / treatments
molecular subtype based treatment
Treatment length
Ask the trial team for details
Visit frequency
Ask the trial team for details
TrialCompass — Clinical Trial Summary

A Study of Molecular Subtyping-based Therapeutic Strategies for Cutaneous T-cell Lymphoma

NCT06436677

Phase: | Status: Recruiting | Priority: Lower

Plain-language summary

This trial is studying molecular subtype based treatment for people with cutaneous T-cell lymphoma (skin lymphoma). The study measures how well this treatment works and monitors for side effects. This trial does not currently list US sites.

Who can join

  • Age 18 Years to 75 Years years
  • See full trial listing for complete eligibility

What's being tested

molecular subtype based treatment (OTHER): The immunohistochemistry algorithm established by the previous research group was used to determine the molecular subtype, and the corresponding treatment plan was selected according to the subtype. Such as for TCyEM patients, interferon-based immunomodulatory therapy was selected, and TCM-type patients were treated with retinoids.

Drugs / treatments: molecular subtype based treatment

Treatment length: Ask the trial team for details

Visit frequency: Ask the trial team for details

Trial design

Non-randomized, blind

Enrollment target: 100 patients

Primary endpoint: time to next treatment (TTNT)

Ages: 18 Years to 75 Years

Start date: 2024-05-09 | Est. completion: 2030-12-31

Locations

0 US sites · 3 total

Contact

Yang Wang, MD | yangwang_dr@bjmu.edu.cn | 86-10-83572350

Sponsor: Peking University First Hospital (OTHER)

Tags

CTCL · any

View on ClinicalTrials.gov

https://clinicaltrials.gov/study/NCT06436677

Prepared using TrialCompass (trialcompass.com) on June 19, 2026. For informational purposes only. Always discuss with your healthcare team.